Your AI-Trained Oncology Knowledge Connection!
Patients with treatment-naïve chronic lymphocytic leukemia with the presence of deletion 17p who received treatment with ibrutinib in the first line were more likely to have poor survival and to discontinue treatment due to progression vs those without.
The primary end point of progression-free survival was not met in the phase 3 SKYSCRAPER-1 trial assessing tiragolumab plus atezolizumab for patients with PD-L1–high locally advanced or metastatic non–small cell lung cancer.
In this installment of Clinical Quandaries, Justine Panian, BS, and colleagues present a case of a 60-year-old Mexican woman with fevers, abdominal pain, and hypertension.
Uday R. Popat, MD, spoke about the decision to use post-transplant cyclophosphamide vs tacrolimus plus methotrexate to prevent graft-vs-host disease.
Alina Markova, MD, highlights important findings from a study assessing topical ruxolitinib INCB018424 phosphate 1.5% cream as a treatment for non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.
Investigators believe that molecular classification could be a predictor of survival in patients with recurrent endometrial cancer.
Patients with advanced human papillomavirus 16–positive cervical cancer appear to benefit from treatment with VB10.16 and atezolizumab.
In an interview with ONCOLOGY®, Megan May, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of dostarlimab as therapy for adult patients with recurrent or advanced solid tumors with deficient mismatch repair.
Tanios Bekaii-Saab, MD, sits with Kristen Ciombor, MD, MSCI, and John Strickler, MD, to examine the COLOMATE platform for patients with colorectal cancer.
Matthew Krebs, MB, PhD, spoke about how subcutaneous amivantamab can best be utilized in future clinical trials.
Investigators identified that in pivotal clinical trials supporting FDA approvals of CAR T-cell therapies for patients with hematologic cancer, Black patients were significantly underrepresented.
Despite having a good rate of treatment adherence, patients who are diagnosed with high-risk stage III colorectal cancer at a younger age may have higher rates of relapse.
The phase 1/2 SPARTACUS trial assessed the use of stereotactic hypofractionated radiation therapy in patients with uterine cancer; the treatment appeared to be well tolerated.
At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about the role of pathology in renal cell carcinoma.
By reading CT scans, machine learning could aid investigators in improving treatment decision making.
Five-year follow-up findings highlighted a durable benefit among patients with advanced renal cell carcinoma following treatment with nivolumab plus ipilimumab compared with sunitinib.
Christine Chung, DO, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® about implications of blood-based molecular markers in pancreatic adenocarcinoma.
Minimal increases in genetic testing and counseling were observed when using a traceback program to contact patients with ovarian cancer and surrogates via phone, and was not time sensitive.
Nicolas Girard, MD, speaks with CancerNetwork® about the updated safety findings of nivolumab and chemotherapy in resectable non–small cell lung cancer.
Pembrolizumab has been approved by the European Commission in 5 indications of solid tumors that are microsatellite instability–high or deficient mismatch repair.
David M. O’Malley, MD, spoke about unmet needs of patients with advanced microsatellite instability–¬high or mismatch repair deficient endometrial carcinoma and the clinical benefit pembrolizumab provides.
Although treatment with polatuzumab vedotin (Polivy) after anti-CD19 CAR T-cell therapy was safe and effective for patients with relapsed/refractory large B-cell lymphoma, it had a short duration of response.
Minimal residual disease status 3 months and 6 months following autologous stem-cell transplant could be predictive of progression-free survival and overall survival outcomes in multiple myeloma.
Patients with metastatic castration-resistant prostate and DNA repair gene defects cancer treated with niraparib were found to experience significant anti-tumor activity.
Nina Shah, MD, spoke about her key takeaways from a sub-analysis of the phase 2 KarMMa trial assessing correlates of complete response among those treated with idecabtagene vicleucel in relapsed/refractory multiple myeloma.
At SGO 2022, Catherine Watson, MD, spoke about how to encourage patients with ovarian cancer to seek genetic testing.
Based on results from an ongoing phase 1/2 trial, the FDA has granted fast track designation to HM432939 for patients with FLT3-mutant relapsed/refractory acute myeloid leukemia.
Updated findings from the phase 3 MONALESSA-3 trial identified a significant overall survival benefit among postmenopausal patients with hormone receptor–positive, HER2-negative breast cancer who were treated with ribociclib and fulvestrant vs matched placebo.
Findings from the phase 3 DESTINY-Breast03 trial have led to the FDA approval of fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive breast cancer.
Sam Klempner, MD, spoke about how clinicians exploring use of ctDNA in gastrointestinal cancers may inform their research with results from other tumor types.
